ReviewOncology reports2026
Dual roles of lactylation modification in gastric cancer: Crosstalk between metabolic reprogramming and epigenetic regulation (Review).
Review in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is among the most prevalent malignant tumors worldwide, and its occurrence and progression are closely associated with metabolic abnormalities and remodeling of the tumor microenvironment. As an emerging metabolism‑related post‑translational modification, lactylation acts as a central hub connecting metabolic reprogramming and epigenetic regulation in tumor cells. The present review systematically describes the reprogramming features of lactate metabolism in the GC microenvironment; dissects the enzymatic system and molecular characteristics of lactylation; and reveals a bidirectional positive feedback loop in which histone H3 lysine 18 lactylation (H3K18la) promotes lactate production by upregulating glycolytic genes, and lactate accumulation, in turn, enhances H3K18la levels. A three‑dimensional regulatory network of 'metabolic reprogramming‑epigenetic regulation‑immune microenvironment remodeling' is thereby established in GC. The present review also reveals the clinical value of lactylation as a prognostic biomarker for GC, proposes combination therapeutic strategies targeting lactylation, and provides a theoretical basis and translational direction for the precise diagnosis and treatment of GC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.